心臓　55/11　2023年11月号

出版社： 日本医学出版
発行日： 2023-11-15
分野： 臨床医学：内科  >  雑誌
ISSN： 05864488
雑誌名：
電子書籍版： 2023-11-15
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：4～8営業日

2,200 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

2,200 円(税込)

購入する

目次

  • Open HEART
    　医局の存在意義と若手医師が今すべきこと

    HEART’s Selection
    あたらしい肺高血圧症
    1．肺高血圧症の定義の変更について
    2．心肺疾患合併の肺動脈性肺高血圧症について
    3．HFpEF‐PHに肺血管拡張薬を投与するべきか
    4．肺動脈性肺高血圧症に対する肺動脈除神経治療
    5．間質性肺炎に伴う肺高血圧症の診断と治療
    6．BMPシグナルを治療ターゲットとする基礎と臨床のクロストーク

    [連載]HEART's　Column
    Authorが語る日本発のクリニカル・エビデンス：論文の解説と発表後の展望
    Features and Outcomes of Histologically Proven Myocarditis With Fulminant Presentation

    [連載]HEART’s Up To Date
    循環器医が知っておくべき最新のエビデンス

    HEART’s Original
    [臨床研究]
    当院過去11年間における冠動脈インターベンション中に発生した冠動脈穿孔例の検討
    [Editorial Comment]
    福田論文に対するEditorial　Comment
    [臨床研究]
    急性心筋梗塞後左室自由壁破裂に対する手術成績の検討
    [Editorial Comment]
    渡部論文に対するEditorial　Comment
    [臨床研究]
    当院における皮下植込み型除細動器の初期成績
    [Editorial Comment]
    塩泡論文に対するEditorial　Comment
    [症例]
    Trastuzumabによる薬剤性心筋症にHeartMate3TMを使用し救命できた1例
    [Editorial Comment]
    茶谷論文に対するEditorial　Comment
    [症例]
    右房内に発生した無症候性の心臓脂肪腫に対して外科的切除を施行した1例

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

【HEART' s Selection】

P.1047 掲載の参考文献
1) World Health Organization : Chronic cor pulmonale. Report of an expert committee. World Health Organ Tech Rep Ser 1961 ; 213 : 35
 
2) Hatano S, Strasser T : Primary Pulmonary Hypertension. Report on a WHO Meeting. Geneva, World Health Organization, 1975
 
3) 日本循環器学会 : 肺高血圧症治療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/10/JCS2017_fukuda_h.pdf (cited 2023 Sep 27)
 
4) Humbert M, Kovacs G, Hoeper MM, et al : 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022 : 43 : 3618-3731
 
5) Ogawa A, Satoh T, Fukuda T, et al : Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension : results of a multicenter registry. Circ Cardiovasc Qual Outcomes 2017 ; 10 : e004029
PubMed
6) Kikuchi H, Goda A, Takeuchi K, et al : Exercise intolerance in chronic thromboembolic pulmonary hypertension after pulmonary angioplasty. Eur Respir J 2020 ; 56 : 1901982
PubMed
7) Aoki T, Sugimura K, Terui Y, et al : Beneficial effects of riociguat on hemodynamic responses to exercise in CTEPH patients after balloon pulmonary angioplasty-a randomized controlled study. Int J Cardiol Heart Vasc 2020 ; 29 : 100579
PubMed
8) Maron BA, Hess E, Maddox TM, et al : Association of borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort : insights from the Veterans Affairs Clinical Assessment, Reporting, and Tracking program. Circulation 2016 ; 133 : 1240-1248
 
9) Maron BA, Brittain EL, Hess E, et al : Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension : a retrospective cohort study. Lancet Respir Med 2020 ; 8 : 873-884
 
P.1052 掲載の参考文献
1) Hoeper MM, Pausch C, Grunig E, et al : Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. J Heart Lung Transplant 2020 ; 39 : 1435-1444
 
2) Hoeper MM, Huscher D, Ghofrani HA, et al : Elderly patients diagnosed with idiopathic pulmonary arterial hypertension : results from the COMPERA registry. Int J Cardiol 2013 ; 168 : 871-880
 
3) Hjalmarsson C, Radegran G, Kylhammar D, et al : Impact of age and comorbidity on risk stratification in idiopathic pulmonary arterial hypertension. Eur Respir J 2018 ; 51 : 1702310
PubMed
4) Humbert M, Kovacs G, Hoeper MM, et al : 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022 ; 43 : 3618-3731
 
5) McLaughlin VV, Vachiery JL, Oudiz RJ, et al : Patients with pulmonary arterial hypertension with and without cardiovascular risk factors : results from the AMBITION trial. J Heart Lung Transplant 2019 ; 38 : 1286-1295
 
6) Olsson KM, Fuge J, Meyer K, et al : More on idiopathic pulmonary arterial hypertension with a low diffusing capacity. Eur Respir J 2017 ; 50 : 1700354
PubMed
7) Opitz CF, Hoeper MM, Gibbs JS, et al : Pre-capillary, combined, and post-capillary pulmonary hypertension : a pathophysiological continuum. J Am Coll Cardiol 2016 ; 68 : 368-378
 
8) Khou V, Anderson JJ, Strange G, et al : Diagnostic delay in pulmonary arterial hypertension : insights from the Australian and New Zealand pulmonary hypertension registry. Respirology 2020 ; 25 : 863-871
 
9) Lewis RA, Thompson AAR, Billings CG, et al : Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension. Eur Respir J 2020 ; 55 : 2000041
PubMed
10) Valentin S, Maurac A, Sitbon O, et al : Outcomes of patients with decreased arterial oxyhaemoglobin saturation on pulmonary arterial hypertension drugs. Eur Respir J 2021 ; 58 : 2004066
PubMed
P.1056 掲載の参考文献
1) 日本循環器学会 : 肺高血圧症治療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/10/JCS2017_fukuda_h.pdf (cited 2023 Oct 15)
 
2) Humbert M, Kovacs G, Hoeper MM, et al : 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022 ; 43 : 3618-3731
 
3) Fayyaz AU, Edwards WD, Maleszewski JJ, et al : Global pulmonary vascular remodeling in pulmonary hypertension associated with heart failure and preserved or reduced ejection fraction. Circulation 2018 ; 137 : 1796-1810
PubMed
4) Hunt JM, Bethea B, Liu X, et al : Pulmonary veins in the normal lung and pulmonary hypertension due to left heart disease. Am J Physiol Lung Cell Mol Physiol 2013 ; 305 : L725-736
 
5) Nguyen QT, Nsaibia MJ, Sirois MG, et al : PBI-4050 reduces pulmonary hypertension, lung fibrosis and right ventricular dysfunction in heart failure. Cardiovasc Res 2020 ; 116 : 171-182
 
6) Guazzi M, Borlaug BA : Pulmonary hypertension due to left heart disease. Circulation 2012 ; 126 : 975-990
 
7) Guazzi M, Naeije R : Pulmonary hypertension in heart failure : pathophysiology, pathobiology, and emerging clinical perspectives. J Am Coll Cardiol 2017 ; 69 : 1718-1734
 
8) Ranchoux B, Nadeau V, Bourgeois A, et al : Metabolic syndrome exacerbates pulmonary hypertension due to left heart disease. Circ Res 2019 ; 125 : 449-466
 
9) Moral-Sanz J, Lopez-Lopez JG, Menendez C, et al : Different patterns of pulmonary vascular disease induced by type 1 diabetes and moderate hypoxia in rats. Exp Physiol 2012 ; 97 : 676-686
 
10) Cayir A, Ugan RA, Albayrak A, et al : The lung endothelin system : a potent therapeutic target with bosentan for the amelioration of lung alterations in a rat model of diabetes mellitus. J Endocrinol Invest 2015 ; 38 : 987-998
 
11) Clemmer JS, Xiang L, Lu S, et al : Hyperglycemia-mediated oxidative stress increases pulmonary vascular permeability. Microcirculation 2016 ; 23 : 221-229
 
12) Obokata M, Reddy YNV, Pislaru SV, et al : Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation 2017 ; 136 : 6-19
 
13) Gopal DM, Santhanakrishnan R, Wang YC, et al : Impaired right ventricular hemodynamics indicate preclinical pulmonary hypertension in patients with metabolic syndrome. J Am Heart Assoc 2015 ; 4 : e001597
PubMed
14) Satoh T, Wang L, Espinosa-Diez C, et al : Metabolic Syndrome Mediates ROS-miR-193b-NFYA-Dependent Downregulation of Soluble Guanylate Cyclase and Contributes to Exercise-Induced Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction. Circulation 2021 ; 144 : 615-637
 
15) Gerges M, Gerges C, Pistritto AM, et al : Pulmonary hypertension in heart failure. epidemiology, right ventricular function, and survival. Am J Respir Crit Care Med 2015 ; 192 : 1234-1246
 
16) Adir Y, Guazzi M, Offer A, et al : Pulmonary hemodynamics in heart failure patients with reduced or preserved ejection fraction and pulmonary hypertension : similarities and disparities. Am Heart J 2017 ; 192 : 120-127
PubMed
17) Califf RM, Adams KF, McKenna WJ, et al : A randomized controlled trial of epoprostenol therapy for severe congestive heart failure : The Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997 ; 134 : 44-54
 
18) Packer M, McMurray J, Massie BM, et al : Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure : results of a pilot study. J Card Fail 2005 ; 11 : 12-20
 
19) Guazzi M : Clinical use of phosphodiesterase-5 inhibitors in chronic heart failure. Circ Heart Fail 2008 ; 1 : 272-280
 
20) Bonderman D, Ghio S, Felix SB, et al : Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction : a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation 2013 ; 128 : 502-511
 
21) Koller B, Steringer-Mascherbauer R, Ebner CH, et al : Pilot Study of Endothelin Receptor Blockade in Heart Failure with Diastolic Dysfunction and Pulmonary Hypertension (BADDHY-Trial). Heart Lung Circ 2017 ; 26 : 433-441
 
22) Vachiery JL, Delcroix M, Al-Hiti H, et al : Macitentan in pulmonary hypertension due to left ventricular dysfunction. Eur Respir J 2018 ; 51 : 1701886
 
23) Redfield MM, Chen HH, Borlaug BA, et al : Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction : a randomized clinical trial. JAMA 2013 ; 309 : 1268-1277
 
24) Belyavskiy E, Ovchinnikov A, Potekhina A, et al : Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension : a randomized open-label pilot study. BMC Cardiovasc Disord 2020 ; 20 : 408
PubMed
25) Guazzi M, Vicenzi M, Arena R, Guazzi MD : Pulmonary hypertension in heart failure with preserved ejection fraction : a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 2011 ; 124 : 164-174
 
26) Dachs TM, Duca F, Rettl R, et al : Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction : the haemoDYNAMIC trial. Eur Heart J 2022 ; 43 : 3402-3413
 
27) Hoendermis ES, Liu LC, Hummel YM, et al : Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension : a randomized controlled trial. Eur Heart J 2015 ; 36 : 2565-2573
 
28) Tedford RJ, Hassoun PM, Mathai SC, et al : Pulmonary capillary wedge pressure augments right ventricular pulsatile loading. Circulation 2012 ; 125 : 289-297
 
29) Tang WHW, Wilcox JD, Jacob MS, et al : Comprehensive diagnostic evaluation of cardiovascular physiology in patients with pulmonary vascular disease : insights from the PVDOMICS Program. Circ Heart Fail 2020 ; 13 : e006363
PubMed
30) Shah SJ, Katz DH, Selvaraj S, et al : Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation 2015 ; 131 : 269-279
 
31) Sugimoto T, Bandera F, Generati G, et al : Left Atrial Dynamics During Exercise in Mitral Regurgitation of Primary and Secondary Origin : Pathophysiological Insights by Exercise Echocardiography Combined With Gas Exchange Analysis. JACC Cardiovasc Imaging 2020 ; 13 (1 Pt 1) : 25-40
 
32) Phosphodiesterase-5 Inhibition in Patients with Heart Failure with Preserved Ejection Fraction and Combined Post- and Pre-Capillary Pulmonary Hypertension (PASSION), A Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Multi-Center, Phase III Trial ; EudraCT number 2017-003688-37 ; European Medicines Agency : Amsterdam, The Netherlands, 2018.
 
33) Burkhoff D, Borlaug BA, Shah SJ, et al : Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF : Results of the Randomized Placebo-Controlled HELP Trial. JACC Heart Fail 2021 ; 9 : 360-370
 
34) Garcia-Alvarez A, Blanco I, Garcia-Lunar I, et al : β3 adrenergic agonist treatment in chronic pulmonary hypertension associated with heart failure (SPHERE-HF) : a double blind, placebo-controlled, randomized clinical trial. Eur J Heart Fail 2023 ; 25 : 373-385
 
35) Shah SJ, Borlaug BA, Chung ES, et al : Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II) : a randomised, multicentre, blinded, sham-controlled trial. Lancet 2022 ; 399 : 1130-1140
 
36) Zhang H, Zhang J, Chen M, et al : Pulmonary Artery Denervation Significantly Increases 6-Min Walk Distance for Patients With Combined Pre- and Post-Capillary Pulmonary Hypertension Associated With Left Heart Failure : The PADN-5 Study. JACC Cardiovasc Interv 2019 ; 12 : 274-284
 
37) Armstrong PW, Lam CSP, Anstrom KJ, et al : Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction : The VITALITY-HFpEF Randomized Clinical Trial. JAMA 2020 ; 324 : 1512-1521
 
38) Pieske B, Maggioni AP, Lam CSP, et al : Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction : results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J 2017 ; 38 : 1119-1127
 
P.1063 掲載の参考文献
1) Vaillancourt M, Chia P, Sarji S, et al : Autonomic nervous system involvement in pulmonary arterial hypertension. Respir Res 2017 ; 18 : 201
PubMed
2) Chen SL, Zhang FF, Xu J, et al : Pulmonary artery denervation to treat pulmonary arterial hypertension : the single-center, prospective, first-in-man PADN-1 study (first-in-man pulmonary artery denervation for treatment of pulmonary artery hypertension). J Am Coll Cardiol 2013 ; 62 : 1092-1100
 
3) Chen SL, Zhang H, Xie DJ, et al : Hemodynamic, functional, and clinical responses to pulmonary artery denervation in patients with pulmonary arterial hypertension of different causes : phase II results from the Pulmonary Artery Denervation-1 study. Circ Cardiovasc Interv 2015 ; 8 : e002837
PubMed
4) Zlupko M, Harhay MO, Gallop R, et al : Evaluation of disease-specific health-related quality of life in patients with pulmonary arterial hypertension. Respir Med 2008 ; 102 : 1431-1438
 
5) Zandstra TE, Notenboom RGE, Wink J, et al : Asymmetry and Heterogeneity : Part and Parcel in Cardiac Autonomic Innervation and Function. Front Physiol 2021 ; 12 : 665298
PubMed
6) Maron BA, Leopold JA : Emerging Concepts in the Molecular Basis of Pulmonary Arterial Hypertension : Part II : Neurohormonal Signaling Contributes to the Pulmonary Vascular and Right Ventricular Pathophenotype of Pulmonary Arterial Hypertension. Circulation 2015 ; 131 : 2079-2091
 
7) Ogo T : Transthoracic Pulmonary Artery Denervation. Arterioscler Thromb Vasc Biol 2019 ; 39 : 979-981
 
8) Juratsch CE, Jengo JA, Castagna J, Laks MM : Experimental pulmonary hypertension produced by surgical and chemical denervation of the pulmonary vasculature. Chest 1980 ; 77 : 525-530
 
9) Chen SL, Zhang YJ, Zhou L, et al : Percutaneous pulmonary artery denervation completely abolishes experimental pulmonary arterial hypertension in vivo. EuroIntervention 2013 ; 9 : 269-276
 
10) Zhou L, Zhang J, Jiang XM, et al : Pulmonary Artery Denervation Attenuates Pulmonary Arterial Remodeling in Dogs With Pulmonary Arterial Hypertension Induced by Dehydrogenized Monocrotaline. JACC Cardiovasc Interv 2015 ; 8 : 2013-2023
 
11) Rothman AM, Arnold ND, Chang W, et al : Pulmonary artery denervation reduces pulmonary artery pressure and induces histological changes in an acute porcine model of pulmonary hypertension. Circ Cardiovasc Interv 2015 ; 8 : e002569
 
12) Huang Y, Liu YW, Pan HZ, et al : Transthoracic Pulmonary Artery Denervation for Pulmonary Arterial Hypertension. Arterioscler Thromb Vasc Biol 2019 ; 39 : 704-718
 
13) Liu Q, Song J, Lu D, et al : Effects of renal denervation on monocrotaline induced pulmonary remodeling. Oncotarget 2017 ; 8 : 46846-46855
 
14) Hoeper MM, Galie N : Letter by Hoeper and Galie Regarding Article, "Hemodynamic, Functional, and Clinical Responses to Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension of Different Causes : Phase II Results From the Pulmonary Artery Denervation-1 Study". Circ Cardiovasc Interv 2016 ; 9 : e003422
PubMed
15) Zhang H, Wei Y, Zhang C, et al : Pulmonary Artery Denervation for Pulmonary Arterial Hypertension : A Sham-Controlled Randomized PADN-CFDA Trial. JACC Cardiovasc Interv 2022 ; 15 : 2412-2423
 
P.1068 掲載の参考文献
1) Hurdman J, Condliffe R, Elliot CA, et al : ASPIRE registry : assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre. Eur Respir J 2012 ; 39 : 945-955
 
2) Humbert M, Kovacs G, Hoeper MM, et al : 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022 ; 43 : 3618-3731
 
3) Nathan SD, Barbera JA, Gaine SP, et al : Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J 2019 ; 53 : 1801914
PubMed
4) Lettieri CJ, Nathan SD, Barnett SD, et al : Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006 ; 129 : 746-752
 
5) Teramachi R, Taniguchi H, Kondoh Y, et al : Progression of mean pulmonary arterial pressure in idiopathic pulmonary fibrosis with mild to moderate restriction. Respirology 2017 ; 22 : 986-990
 
6) Rahaghi FF, Kolaitis NA, Adegunsoye A, et al : Screening Strategies for Pulmonary Hypertension in Patients With Interstitial Lung Disease : A Multidisciplinary Delphi Study. Chest 2022 ; 162 : 145-155
 
7) Arcasoy SM, Christie JD, Ferrari VA, et al : Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003 ; 167 : 735-740
 
8) Shin S, King CS, Puri N, et al : Pulmonary artery size as a predictor of outcomes in idiopathic pulmonary fibrosis. Eur Respir J 2016 ; 47 : 1445-1451
 
9) Chung JH, Montner SM, Adegunsoye A, et al : CT findings associated with survival in chronic hypersensitivity pneumonitis. Eur Radiol 2017 ; 27 : 5127-5135
 
10) Alkhanfar D, Shahin Y, Alandejani F, et al : Severe pulmonary hypertension associated with lung disease is characterised by a loss of small pulmonary vessels on quantitative computed tomography. ERJ Open Res 2022 ; 8 : 00503-2021
 
11) Hamada K, Nagai S, Tanaka S, et al : Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest 2007 ; 131 : 650-656
 
12) Furukawa T, Kondoh Y, Taniguchi H, et al : A scoring system to predict the elevation of mean pulmonary arterial pressure in idiopathic pulmonary fibrosis. Eur Respir J 2018 ; 51 : 1701311
PubMed
13) Olsson KM, Hoeper MM, Pausch C, et al : Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease : results from the COMPERA registry. Eur Respir J 2021 ; 58 : 2101483
PubMed
14) Raghu G, Remy-Jardin M, Richeldi L, et al : Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults : An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 2022 ; 205 : e18-e47
 
15) Sakao S, Tanabe N, Tatsumi K : Hypoxic Pulmonary Vasoconstriction and the Diffusing Capacity in Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis. J Am Heart Assoc 2019 ; 8 : e013310
PubMed
16) King TE Jr, Behr J, Brown KK, et al : BUILD-1 : a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008 ; 177 : 75-81
 
17) King TE Jr, Brown KK, Raghu G, et al : BUILD-3 : a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011 ; 184 : 92-99
 
18) Raghu G, Behr J, Brown KK, et al : Treatment of idiopathic pulmonary fibrosis with ambrisentan : a parallel, randomized trial. Ann Intern Med 2013 ; 158 : 641-649
 
19) Raghu G, Million-Rousseau R, Morganti A, et al ; MUSIC Study Group : Macitentan for the treatment of idiopathic pulmonary fibrosis : the randomised controlled MUSIC trial. Eur Respir J 2013 ; 42 : 1622-1632
 
20) Saggar R, Khanna D, Vaidya A, et al : Changes in right heart haemodynamics and echocardiographic function in an advanced phenotype of pulmonary hypertension and right heart dysfunction associated with pulmonary fibrosis. Thorax 2014 ; 69 : 123-129
 
21) Zimmermann GS, von Wulffen W, Huppmann P, et al : Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors. Respirology 2014 ; 19 : 700-706
 
22) Corte TJ, Keir GJ, Dimopoulos K, et al : Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2014 ; 190 : 208-217
 
23) Hoeper MM, Behr J, Held M, et al : Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial Pneumonias. PLoS One 2015 ; 10 : e0141911
PubMed
24) Tanabe N, Kumamaru H, Tamura Y, et al : Multi-Institutional Prospective Cohort Study of Patients With Pulmonary Hypertension Associated With Respiratory Diseases. Circ J 2021 ; 85 : 333-342
 
25) Ghofrani HA, Wiedemann R, Rose F, et al : Sildenafil for treatment of lung fibrosis and pulmonary hypertension : a randomised controlled trial. Lancet 2002 ; 360 : 895-900
 
26) Tanabe N, Taniguchi H, Tsujino I, et al : Multi-institutional retrospective cohort study of patients with severe pulmonary hypertension associated with respiratory diseases. Respirology 2015 ; 20 : 805-812
 
27) Nathan SD, Behr J, Collard HR, et al : Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP) : a randomised, placebo-controlled phase 2b study. Lancet Respir Med 2019 ; 7 : 780-790
 
28) Waxman A, Restrepo-Jaramillo R, Thenappan T, et al : Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease. N Engl J Med 2021 ; 384 : 325-334
 
29) Nathan SD, Waxman A, Rajagopal S, et al : Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension : a post-hoc analysis of the INCREASE study. Lancet Respir Med 2021 ; 9 : 1266-1274
 
P.1073 掲載の参考文献
1) Tamura Y, Kumamaru H, Satoh T, et al : Effectiveness and Outcome of Pulmonary Arterial Hypertension-Specific Therapy in Japanese Patients With Pulmonary Arterial Hypertension. Circ J 2017 ; 82 : 275-282
 
2) Lane KB, Machado RD, Pauciulo MW, et al : International PPH Consortium. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 2000 ; 26 : 81-84
 
3) Trembath RC, Thomson JR, Machado RD, et al : Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001 ; 345 : 325-334
 
4) Soubrier F, Chung WK, Machado R, et al : Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 2013 ; 62 (25 Suppl) : D13-D21
 
5) Atkinson C, Stewart S, Upton PD, et al : Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 2002 ; 105 : 1672-1678
 
6) Bloise E, Ciarmela P, Dela Cruz C, et al : Activin A in mammalian physiology. Physiol Rev 2019 ; 99 : 739-780
 
7) Ryanto GRT, Musthafa A, Hara T, Emoto N : Inactivating the Uninhibited : The Tale of Activins and Inhibins in Pulmonary Arterial Hypertension. Int J Mol Sci 2023 ; 24 : 3332
PubMed
8) Guignabert C, Humbert M : Targeting transforming growth factor-β receptors in pulmonary hypertension. Eur Respir J 2021 ; 57 : 2002341
 
9) Ryanto GRT, Ikeda K, Miyagawa K, et al : An endothelial activin A-bone morphogenetic protein receptor type 2 link is overdriven in pulmonary hypertension. Nat Commun 2021 ; 12 : 1720
PubMed
10) Yung LM, Yang P, Joshi S, et al : ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension. Sci Transl Med 2020 ; 12 : eaaz5660
PubMed
11) Joshi SR, Liu J, Bloom T, et al : Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension. Sci Rep 2022 ; 12 : 7803
PubMed
12) Rong W, Liu C, Li X, et al : Caspase-8 promotes pulmonary hypertension by activating macrophage-associated inflammation and IL-1β (interleukin 1β) production. Arterioscler Thromb Vasc Biol 2022 ; 42 : 613-631
 
13) Guignabert C, Savale L, Boucly A, et al : Serum and Pulmonary Expression Profiles of the Activin Signaling System in Pulmonary Arterial Hypertension. Circulation 2023 ; 147 : 1809-1822
 
14) Hadwiono MR, Hartopo AB, Wasityastuti W, et al : Increased serum activin A level in congenital heart disease-associated pulmonary artery hypertension : A comparative study from the COHARD-PH registry. Pulm Circ 2023 ; 13 : e12280
PubMed
15) Humbert M, McLaughlin V, Gibbs JSR, et al : Sotatercept for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2021 ; 384 : 1204-1215
 
16) Hoeper MM, Badesch DB, Ghofrani HA, et al : Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2023 ; 388 : 1478-1490
 
17) Spiekerkoetter E, Sung YK, Sudheendra D, et al : Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 2015 ; 192 : 254-257
 

【連載】

P.1078 掲載の参考文献
1) Nagai T, Inomata T, Kohno T, et al : JCS 2023 Guideline on the Diagnosis and Treatment of Myocarditis. Circ J 2023 ; 87 : 674-754
 
2) Ammirati E, Cipriani M, Lilliu M, et al : Survival and Left Ventricular Function Changes in Fulminant Versus Nonfulminant Acute Myocarditis. Circulation 2017 ; 136 : 529-545
 
3) Kanaoka K, Onoue K, Terasaki S, Nakano T, Nakai M, Sumita Y, Hatakeyama K, Terasaki F, Kawakami R, Iwanaga Y, Miyamoto Y, Saito Y ; Japanese Registry of Fulminant Myocarditis Investigators : Features and Outcomes of Histologically Proven Myocarditis With Fulminant Presentation. Circulation 2022 ; 146 : 1425-1433
 

【HEART' s Original】

P.1087 掲載の参考文献
1) 新家俊郎 : 冠動脈ステントの進化. 冠疾患誌 2016 ; 22 : 34-38
 
2) Bonaa KH, Mannsverk J, Wiseth R, et al : Drug-eluting or bare-metal stents for coronary artery disease. N Engl J Med 2016 ; 375 : 1242-1252
 
3) McFadden EP, Stabile E, Regar E, et al : Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004 ; 364 : 1519-1521
 
4) Aoki J, Kirtane A, Leon MB, Dangas G : Coronary artery aneurysms after drug-eluting stent implantation. JACC Cardiovasc Interv 2008 ; 1 : 14-21
 
5) Imai M, Kadota K, Goto T, et al : Incidence, Risk FacContrast Staining After Sirolimus-Eluting Stent Implantation. Circulation 2011 ; 123 : 2382-2391
 
6) Ellis SG, Ajluni S, Arnold AZ, et al : Increased coronary perforation in the new device era. Incidence, classification, management, and outcome. Circulation 1994 ; 90 : 2725-2730
 
7) 竹内庸浩, 西堀祥晴, 丸山貴生, ほか : 冠動脈穿孔に起因した心停止の1救命例. 呼吸と循環 2013 ; 61 : 85-91
 
8) 須賀俊博, 吉村裕子, 高松寛人, ほか : ステント留置後拡張で冠動脈穿孔をきたしたもののperfusion balloonで良好に止血できた1例. 心臓 2013 ; 45 : 1033-1038
 
9) Mikhail P, Howden N, Monjur M, et al : Coronary perforation incidence, outcomes and temporal trends (COPIT) : a systematic review and meta-analysis. Open Heart 2022 ; 9 : e002076
PubMed
10) Shaukat A, Tajti P, Sandoval Y, et al : Incidence, predictors, management and outcomes of coronary perforations. Catheter Cardiovasc Interv 2019 ; 93 : 48-56
 
11) Ford TJ, Adamson C, Morrow AJ, et al : Coronary Artery Perforations : Glasgow Natural History Study of Covered Stent Coronary Interventions (GNOCCI) Study. J Am Heart Assoc 2022 ; 11 : e024492
PubMed
12) Giannini F, Candilio L, Mitomo S, et al : A Practical Approach to the Management of Complications During Percutaneous Coronary Intervention. JACC Cardiovasc Interv 2018 ; 11 : 1797-1810
 
13) Kuno T, Numasawa Y, Sawano M, et al : Real-world use of intravascular ultrasound in Japan : a report from contemporary multicenter PCI registry. Heart Vessels 2019 ; 34 : 1728-1739
 
14) Sapontis J, Salisbury AC, Yeh RW, et al : Early Procedural and Health Status Outcomes After Chronic Total Occlusion Angioplasty : A Report From the OPEN-CTO Registry (Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion Hybrid Procedures). JACC Cardiovasc Interv 2017 ; 10 : 1523-1534
 
15) Pavani M, Cerrato E, Franze A, et al : Grade 3 coronary artery perforations in chronic total occlusion-percutaneous coronary intervention : Mechanisms, locations, and outcomes from the G3CAP Registry. Catheter Cardiovasc Interv 2022 ; 100 : 190-198
 
16) Habara M, Tsuchikane E, Shimizu K, et al : Japanese multicenter registry evaluating the antegrade dissection reentry with cardiac computerized tomography for chronic coronary total occlusion. Cardiovasc Interv Ther 2022 ; 37 : 116-127
 
17) 小川崇之 : 心血管インターベンションのコツとピットフォール〔マイクロカテーテルの使用〕. CIRCULATION Up-to-Date 2013 ; 8 : 86-97
 
18) Kandzari DE, Sarao RC, Waksman R : Clinical experience of the PK Papyrus covered stent in patients with coronary artery perforations : results from a multi-center humanitarian device exemption survey. Cardiovasc Revasc Med 2022 ; 43 : 97-101
 
19) Pavani M, Cerrato E, Latib A, et al : Acute and long-term outcomes after polytetrafluoroethylene or pericardium covered stenting for grade 3 coronary artery perforations : Insights from G3-CAP registry. Catheter Cardiovasc Interv 2018 ; 92 : 1247-1255
PubMed
20) Lemmert ME, van Bommel RJ, Diletti R, et al : Clinical Characteristics and Management of Coronary Artery Perforations : A Single-Center 11-Year Experience and Practical Overview. J Am Heart Assoc 2017 ; 6 : e007049
PubMed
21) Simsek C, Vos J, IJsselmuiden A, et al : Coronary artery perforation after Shockwave Intravascular Lithotripsy. JACC Case Rep 2020 ; 2 : 247-249
 
22) Spertus JA, Jones PG, Maron DJ, et al : Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease. N Engl J Med 2020 ; 382 : 1408-1419
 
P.1090 掲載の参考文献
1) Kinnaird T, Kwok CS, Kontopantelis E, et al : Incidence, determinants and outcomes of coronary perforation during percutaneous coronary intervention in the United Kingdom between 2006 and 2013. An analysis of 527121 cases from the British Cardiovascular Intervention Society Database. Circ Cardiovasc Interv 2016 ; 9 : e003449
 
2) Spertus JA, Jones PG, Maron DJ, et al : Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease. N Engl J Med 2020 ; 382 : 1408-1419
 
3) Ellis SG, Roubin GS, King SB 3rd, et al : Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty. Circulation 1988 ; 77 : 372-379
 
4) Giannini F, Candilio L, Mitomo S, et al : A Practical Approach to the Management of Complications During Percutaneous Coronary Intervention. JACC Cardiovasc Interv 2018 ; 11 : 1797-1810
 
P.1096 掲載の参考文献
1) Elbadawi A, Elgendy IY, Mahmoud K, et al : Temporal Trends and Outcomes of Mechanical Complications in Patients With Acute Myocardial Infarction. JACC Cardiovasc Interv 2019 ; 12 : 1825-1836
 
2) Honda S, Asaumi Y, Yamane T, et al : Trends in the clinical and pathological characteristics of cardiac rupture in patients with acute myocardial infarction over 35 years. J Am Heart Assoc 2014 ; 3 : e000984
PubMed
3) Matteucci M, Formica F, Kowalewski M, et al : Meta-analysis of surgical treatment for postinfarction left ventricular free-wall rupture. J Card Surg 2021 ; 36 : 3326-3333
 
4) FitzGibbon GM, Hooper GD, Heggtveit HA : Successful surgical treatment of postinfarction external cardiac rupture. J Thorac Cardiovasc Surg 1972 ; 63 : 622-630
 
5) Nunez L, de la Llana R, Lopez Sendon J, et al : Diagnosis and treatment of subacute free wall ventricular rupture after infarction. Ann Thorac Surg 1983 ; 35 : 525-529
 
6) Okamura H : Sutureless repair techniques for post-infarction left ventricular free wall rupture. Ann Cardiothorac Surg 2022 ; 11 : 268-272
 
7) 奈良原裕, 尾頭厚, 村田登 : Blow out型左室自由壁破裂に対してsutureless techniqueを用いて救命し得た1例. 日本心臓血管外科学会雑誌 2010 ; 39 : 254-257
 
8) Holubec T, Caliskan E, Bettex D, Maisano F : Repair of post-infarction left ventricular free wall rupture using an extracellular matrix patch. Eur J Cardiothorac Surg 2015 ; 48 : 800-803
 
9) The Survey Committee of Japanese Association for Coronary Artery Surgery (JACAS) : Coronaey artery surgery results in 2020. http://www.jacas.org/data/pdf/slide_2020.pdf (cited 2023 Apr 01)
 
10) Montegut FJ Jr : Left ventricular rupture secondary to myocardial infarction. Report of survival with surgical repair. Ann Thorac Surg 1972 ; 14 : 75-78
 
11) Matteucci M, Fina D, Jiritano F, et al : Treatment strategies for post-infarction left ventricular free-wall rupture. Eur Heart J Acute Cardiovasc Care 2019 ; 8 : 379-387
 
12) Okamura H, Kimura N, Mieno M, et al : Sutureless repair for postinfarction left ventricular free wall rupture. J Thorac Cardiovasc Surg 2019 ; 158 : 771-777
 
13) Muto A, Nishibe T, Kondo Y, et al : Sutureless repair with TachoComb sheets for oozing type postinfarction cardiac rupture. Ann Thorac Surg 2005 ; 79 : 2143-2145
 
14) Raffa GM, Tarelli G, Patrini D, Settepani F : Sutureless repair for postinfarction cardiac rupture : a simple approach with a tissue-adhering patch. J Thorac Cardiovasc Surg 2013 ; 145 : 598-599
 
15) Matteucci M, Fina D, Jiritano F, et al : Sutured and Sutureless repair of postinfarction left ventricular free-wall rupture : a systematic review. Eur J Cardiothorac Surg 2019 ; 56 : 840-848
 
16) 竹村隆広, 島村吉衛, 山崎琢磨 : 左室自由壁破裂 発症前に重度心不全を合併した左室自由壁破裂に対するinfarct exclusion. 胸部外科 2005 ; 58 : 271-275
 
17) Kato Y, Fukui T, Tabata M, Takanashi S : Successful infarct exclusion for postinfarction left ventricular free wall rupture. Interact Cardiovasc Thorac Surg 2013 ; 16 : 900-902
 
P.1097 掲載の参考文献
1) 日本冠動脈外科学会 : 全国アンケート調査. http://www.jacas.org/enquete/index.html (cited 2023 Oct 01)
 
2) Padro JM, Caralps JM, Montoya JD, et al : Sutureless repair of postinfarction cardiac rupture. J Card Surg 1988 ; 3 : 491-493
 
3) Bachet J, Tedori G, Gondot B, et al : Replacement of the transverse aortic arch during emergency surgery on type A aortic dissection. Presented at the 68th Annual Meeting of the American Association for Thoracic Surgery. Los Angeles, CA, April 18-20, 1988
 
4) Komiya T : Surgical treatment of left ventricular free wall rupture : patch-glue technique. J Jpn Coron Assoc 2007 ; 13 : 246-250
 
5) Misawa Y : Off-pump sutureless repair for ischemic left ventricular free wall rupture : a systematic review. J Cardiothorac Surg 2017 ; 12 : 36
PubMed
6) Takago S, Nishida S, Koyama K, et al : Sutureless repair with Hydrofit(R) and bovine pericardial patch for oozing-type postinfarction cardiac rupture. Gen Thorac Cardiovasc Surg 2023 Aug 23. doi : 10.1007/s11748-023-01972-1. [Online ahead of print]
 
7) Ishii H, Endo H, Tsuchiya H, et al : Off-pump hemostasis for left ventricular rupture after myocardial infarction with Hydrofit(R) and Surgicel(R). Gen Thorac Cardiovasc Surg 2018 ; 66 : 753-755
 
8) Lewis AJ, Burchell HB, Titus JL : Clinical and pathologic features of postinfarction cardiac rupture. Am J Cardiol 1969 ; 23 : 43-53
 
9) Saito S, Shibasaki I, Matsuoka T, et al : Impella support as a bridge to heart surgery in patients with cardiogenic shock. Interact Cardiovasc Thorac Surg 2022 ; 35 : ivac088
PubMed
10) Ishikawa N, Hirofuji A, Kunioka S, et al : Impella CP for treatment of left ventricular free-wall rupture after myocardial infarction : Report of a case. J Surg Case Rep 2020 ; 2020 : rjaa263
 
P.1106 掲載の参考文献
1) The Antiarrhythmics Versus Implantable Defibrillators (AIVD) Investigators : A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997 ; 337 : 1576-1583
 
2) 一般社団法人 日本不整脈デバイス工業会 : 都道府県別ICD, CRT-D植込台数年次推移 (日本不整脈デバイス工業会調べによる). https://www.jadia.or.jp/medical/crt-d.html (cited 2023 Feb 04)
 
3) Tonegawa-Kuji R, Inoue YY, Nakai M, et al : Current clinical practice of subcutaneous implantable cardioverter-defibrillator : Analysis using the JROAD-DPC database. Heart Rhythm 2022 ; 19 : 909-916
 
4) Knops RE, Olde Nordkamp LRA, Delnoy PHM, et al : Subcutaneous or transvenous defibrillator therapy. N Engl J Med 2020 ; 383 : 526-536
PubMed
5) Boersma L, Barr C, Knops R, et al ; EFFORTLESS Investigator Group : Implant and midterm outcomes of the Subcutaneous Implantable Cardioverter-Defibrillator Registry : The EFFORTLESS Study. J Am Coll Cardiol 2017 ; 70 : 830-841
 
6) Gold MR, Lambiase PD, El-Chami MF, et al : Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial. Circulation 2021 ; 143 : 7-17
 
7) Matsuo K, Akahoshi M, Nakashima E, et al : The prevalence, incidence and prognostic value of the Brugada-type electrocardiogram : a population-based study of four decades. J Am Coll Cardiol 2001 ; 38 : 765-770
 
8) Bardy GH, Smith WM, Hood MA, et al : An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med 2010 ; 363 : 36-44
 
9) Burke MC, Gold MR, Knight BP, et al : Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator : 2-Year Results From a Pooled Analysis of the IDE Study and EFFORTLESS Registry. J Am Coll Cardiol 2015 ; 65 : 1605-1615
 
10) Heist EK, Belalcazar A, Stahl W, et al : Determinants of Subcutaneous Implantable Cardioverter-Defibrillator Efficacy : A Computer Modeling Study. JACC Clin Electrophysiol 2017 ; 3 : 405-414
 
11) Knops RE, Pepplinkhuizen S, Delnoy PPHM, et al : Device-related complications in subcutaneous versus transvenous ICD : a secondary analysis of the PRAETORIAN trial. Eur Heart J 2022 ; 43 : 4872-4883
 
12) Weiss R, Knight BP, Gold MR, et al : Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. Ciculation 2013 ; 128 : 944-953
 
13) Auricchio A, Meijer A, Kurita T, et al : Safety, efficacy, and performance of new discrimination algorithms to reduce inappropriate and unnecessary shocks : the PainFree SST clinical study design. Europace 2011 ; 13 : 1484-1493
 
14) Iavarone M, Rago A, Nigro G, et al : Inappropriate shocks due to air entrapment in patients with subcutaneous implantable cardioverter-defibrillator : A meta-summary of case reports. Pacing Clin Electrophysiol 2022 ; 45 : 1210-1215
 
P.1109 掲載の参考文献
1) Satake H, Fukuda K, Sakata Y, et al : Current status of primary prevention of sudden cardiac death with implantable cardioverter defibrillator in patients with chronic heart failure--a report from the CHART-2 Study. Circ J 2015 ; 79 : 381-390
 
2) Kabutoya T, Mitsuhashi T, Shimizu A, et al : Prognosis of Japanese Patients With Coronary Artery Disease Who Underwent Implantable Cardioverter Defibrillator Implantation-The JID-CAD Study. Circ Rep 2021 ; 3 : 69-76
 
3) Aonuma K, Ando K, Kusano K, et al : Primary results from the Japanese Heart Failure and Sudden Cardiac Death Prevention Trial (HINODE). ESC Heart Fail 2022 ; 9 : 1584-1596
 
4) Healey JS, Krahn AD, Bashir J, et al : Perioperative Safety and Early Patient and Device Outcomes Among Subcutaneous Versus Transvenous Implantable Cardioverter Defibrillator Implantations : A Randomized, Multicenter Trial. Ann Intern Med 2022 ; 175 : 1658-1665
 
5) 佐々木真吾・編 : S-ICDのすべて. 東京 : 医学図書出版 ; 2023.
 
P.1116 掲載の参考文献
1) 清野精彦 : 癌化学療法による心毒性. 心臓 2014 ; 46 : 322-329
 
2) Bowles EJ, Wellman R, Feigelson HS, et al : Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment : a retrospective cohort study. J Natl Cancer Inst 2012 ; 104 : 1293-1305
 
3) Eiger D, Ponde NF, Agbor-Tarh D, et al : Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial. Br J Cancer 2020 ; 122 : 1453-1460
PubMed
4) Plana JC, Galderisi M, Barac A, et al : Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy : a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2014 ; 15 : 1063-1093
 
5) Perez IE, Taveras Alam S, Hernandez GA, Sancassani R : Cancer Therapy-Related Cardiac Dysfunction : An Overview for the Clinician. Clin Med Insights Cardiol 2019 ; 13 : 1179546819866445
PubMed
6) 塩瀬明, 田ノ上禎久 : 新規植込型補助人工心臓デバイス : HVADとHeartMate3. 心臓 2019 ; 51 : 1120-1128
 
7) 日本循環器学会 : 循環器病ガイドラインシリーズ 2016年度版 : 心臓移植に関する提言. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2016_isobe_d.pdf (cited 2022 Oct 05)
 
8) 日本循環器学会/日本心臓血管外科学会/日本胸部外科学会/日本血管外科学会 : 2021年改訂版 重症心不全に対する植込型補助人工心臓治療ガイドライン. https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Ono_Yamaguchi.pdf (cited 2022 Oct 05)
 
P.1118 掲載の参考文献
1) Ali MT, Yucel E, Bouras S, et al : Myocardial Strain Is Associated with Adverse Clinical Cardiac Events in Patients Treated with Anthracyclines. J Am Soc Echocardiogr 2016 ; 29 : 522-527
 
2) Lyon AR, Lopez-Fernandez T, Couch LS, et al : 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022 ; 43 : 4229-4361
 
3) 日本臨床腫瘍学会/日本腫瘍循環器学会 : Onco-cardiologyガイドライン. 東京 : 南江堂 ; 2023.
 
P.1124 掲載の参考文献
1) Shu S, Wang J, Zheng C : From pathogenesis to treatment, a systemic review of cardiac lipoma. J Cardiothorac Surg 2021 ; 16 : 1
 
2) Maia Alves R, Gamboa C : Cardiac Lipoma of the Interventricular Septum. Eur J Case Rep Intern Med 2020 ; 7 : 001685
PubMed
3) Singh S, Singh M, Kovacs D, et al : A rare case of a intracardiac lipoma. Int J Surg Case Rep 2015 ; 9 : 105-108
 
4) Habertheuer A, Andreas M, Wiedemann D, et al : A rare case of obstructive right atrial lipoma. Ann R Coll Surg Engl 2014 ; 96 : e39-41
 
5) Alameddine AK, Alimov VK, Turner GS Jr, Deaton DW : Surgical pitfalls of excising an intramyocardial lipoma. J Thorac Cardiovasc Surg 2011 ; 141 : 592-594
 
6) Shah OA, Badran A, Kaarne M, Velissaris T ; Right atrial and SVC infiltrating mass-the entity of infiltrating lipoma. J Cardiothorac Surg 2019 ; 14 : 210
PubMed
7) Shu S, Yuan H, Kong X, et al : The value of multimodality imaging in diagnosis and treatment of cardiac lipoma. BMC Med Imaging 2021 ; 21 : 71
PubMed
8) Fang L, He L, Chen Y, et al : Infiltrating Lipoma of the Right Ventricle Involving the Interventricular Septum and Tricuspid Valve : Report of a Rare Case and Literature Review. Medicine (Baltimore) 2016 ; 95 : e2561
PubMed
9) Zhang J, Chong E, Chai P, Poh KK : Contrasting fatty involvement of the right ventricle : lipoma versus lipomatous hypertrophy. Singapore Med J 2009 ; 50 : e342-345
 
10) Vadivelu R, Bohora S, Bachani N, et al : Ventricular tachycardia as the presenting feature in two patients with cardiac lipoma and cardiac fibroma. Indian Pacing Electrophysiol J 2021 ; 21 : 62-64
 
11) Vriz O, Ahmed MM, Kharabsheha S, et al : Ventricular tachycardia : beginning and ending fate of a benign invasive cardiac lipoma. Monaldi Arch Chest Dis 2020 ; 90 (3). doi : 10.4081/monaldi.2020.1288.
 
12) Shenthar J, Sharma R, Rai MK, Simha P : Infiltrating cardiac lipoma presenting as ventricular tachycardia in a young adult. Indian Heart J 2015 ; 67 : 359-361
 
13) Bagwan IN, Sheppard MN : Cardiac lipoma causing sudden cardiac death. Eur J Cardiothorac Surg 2009 ; 35 : 727
PubMed
14) D'Errico S, Mazzanti A, Frati P, Fineschi V : Conduction disorder and primary cardiac tumor : a fatal case of multiple lipomas of the right atrium. J Geriatr Cardiol 2019 ; 16 : 431-433
 
15) Parmaksiz HT, Elonu O, Duman U, Seyfeli E : A case of symptomatic right atrial lipoma. Turk Kardiyol Dern Ars 2012 ; 40 : 361-363
 
16) 西田洋文, 須藤義夫, 浮田英生, 中島伸之 : 心房中隔に発生した浸潤性脂肪腫の1手術例. 日心外会誌 2004 ; 33 : 329-332
 
17) Shen J, Fang Z, Zhang Y, Guo Y : Primary cardiac dedifferentiated liposarcoma in a middle-aged female : a case report. J Cardiothorac Surg 2019 ; 14 : 156
 
18) Goto T, Ohte N, Tani T, et al : Malignant Nature of Cardiac Liposarcoma Revealed by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomographic Imaging. Intern Med 2012 ; 51 : 1367-1370
 
19) Crago AM, Dickson MA : Liposarcoma : Multimodality Management and Future Targeted Therapies. Surg Oncol Clin N Am 2016 ; 25 : 761-773
 
20) Zhu SB, Zhu J, Liu Y, Wang RP : Surgical Treatment of a Giant Symptomatic Cardiac Lipoma. J Thorac Oncol 2013 ; 8 : 1341-1342
 
21) Zhu J, Liu Y, Xi EP, Zhu SB : A giant symptomatic cardiac lipoma recurring at the fifth year. Int J Clin Exp Med 2015 ; 8 : 14173-14175
 

書評

最近チェックした商品履歴

Loading...